103 related articles for article (PubMed ID: 34480095)
1. Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer.
Chatzipli A; Bonnefoi H; MacGrogan G; Sentis J; Cameron D; Poncet C; ; Iggo R
Br J Cancer; 2021 Nov; 125(10):1356-1364. PubMed ID: 34480095
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.
Mukai H; Uemura Y; Akabane H; Watanabe T; Park Y; Takahashi M; Sagara Y; Nishimura R; Takashima T; Fujisawa T; Hozumi Y; Kawahara T
Br J Cancer; 2021 Oct; 125(9):1217-1225. PubMed ID: 34480096
[TBL] [Abstract][Full Text] [Related]
3. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
[TBL] [Abstract][Full Text] [Related]
4. Benefits of Trimodality Therapy Compared with Systemic Therapy Alone in Male Patients with Stage IV Breast Cancer.
Stahl KA; Wong W; Olecki EJ; McLaughlin C; Perez-Holguin R; Lewcun JA; Dodge D; Shen C
Ann Surg Oncol; 2022 Feb; 29(2):1005-1017. PubMed ID: 34480282
[TBL] [Abstract][Full Text] [Related]
5. Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue.
Lapidari P; Djehal N; Havas J; Gbenou A; Martin E; Charles C; Dauchy S; Pistilli B; Cadeau C; Bertaut A; Everhard S; Martin AL; Coutant C; Cottu P; Menvielle G; Dumas A; Andre F; Michiels S; Vaz-Luis I; Di Meglio A
Breast Cancer Res Treat; 2021 Dec; 190(3):517-529. PubMed ID: 34559354
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Fukada I; Ito Y; Kondo N; Ohtani S; Hattori M; Tokunaga E; Matsunami N; Mashino K; Kosaka T; Tanabe M; Yotsumoto D; Yamanouchi K; Sawaki M; Kashiwaba M; Kawabata H; Kuroi K; Morita S; Ohno S; Toi M; Masuda N
Breast Cancer Res Treat; 2021 Dec; 190(3):425-434. PubMed ID: 34554370
[TBL] [Abstract][Full Text] [Related]
7. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
[TBL] [Abstract][Full Text] [Related]
8. Trajectories of alcohol consumption during life and the risk of developing breast cancer.
Donat-Vargas C; Guerrero-Zotano Á; Casas A; Baena-Cañada JM; Lope V; Antolín S; Garcia-Saénz JÁ; Bermejo B; Muñoz M; Ramos M; de Juan A; Jara Sánchez C; Sánchez-Rovira P; Antón A; Brunet J; Gavilá J; Salvador J; Arriola Arellano E; Bezares S; Fernández de Larrea-Baz N; Pérez-Gómez B; Martín M; Pollán M
Br J Cancer; 2021 Oct; 125(8):1168-1176. PubMed ID: 34483338
[TBL] [Abstract][Full Text] [Related]
9. Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis.
Pizzamiglio S; Ciniselli CM; Triulzi T; Gargiuli C; De Cecco L; de Azambuja E; Fumagalli D; Sotiriou C; Harbeck N; Izquierdo M; Nuciforo P; Huober J; Cappelletti V; Cinieri S; Piccart M; Daidone MG; Pruneri G; Colombo MP; Tagliabue E; Verderio P; Di Cosimo S
Clin Cancer Res; 2021 Dec; 27(23):6307-6313. PubMed ID: 34548320
[TBL] [Abstract][Full Text] [Related]
10. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Del Mastro L; Mansutti M; Bisagni G; Ponzone R; Durando A; Amaducci L; Campadelli E; Cognetti F; Frassoldati A; Michelotti A; Mura S; Urracci Y; Sanna G; Gori S; De Placido S; Garrone O; Fabi A; Barone C; Tamberi S; Bighin C; Puglisi F; Moretti G; Arpino G; Ballestrero A; Poggio F; Lambertini M; Montemurro F; Bruzzi P;
Lancet Oncol; 2021 Oct; 22(10):1458-1467. PubMed ID: 34543613
[TBL] [Abstract][Full Text] [Related]
11. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
Mulcahy MF; Mahvash A; Pracht M; Montazeri AH; Bandula S; Martin RCG; Herrmann K; Brown E; Zuckerman D; Wilson G; Kim TY; Weaver A; Ross P; Harris WP; Graham J; Mills J; Yubero Esteban A; Johnson MS; Sofocleous CT; Padia SA; Lewandowski RJ; Garin E; Sinclair P; Salem R;
J Clin Oncol; 2021 Dec; 39(35):3897-3907. PubMed ID: 34541864
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab Deruxtecan in
Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
[TBL] [Abstract][Full Text] [Related]
13. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Symmans WF; Yau C; Chen YY; Balassanian R; Klein ME; Pusztai L; Nanda R; Parker BA; Datnow B; Krings G; Wei S; Feldman MD; Duan X; Chen B; Sattar H; Khazai L; Zeck JC; Sams S; Mhawech-Fauceglia P; Rendi M; Sahoo S; Ocal IT; Fan F; LeBeau LG; Vinh T; Troxell ML; Chien AJ; Wallace AM; Forero-Torres A; Ellis E; Albain KS; Murthy RK; Boughey JC; Liu MC; Haley BB; Elias AD; Clark AS; Kemmer K; Isaacs C; Lang JE; Han HS; Edmiston K; Viscusi RK; Northfelt DW; Khan QJ; Leyland-Jones B; Venters SJ; Shad S; Matthews JB; Asare SM; Buxton M; Asare AL; Rugo HS; Schwab RB; Helsten T; Hylton NM; van 't Veer L; Perlmutter J; DeMichele AM; Yee D; Berry DA; Esserman LJ
JAMA Oncol; 2021 Nov; 7(11):1654-1663. PubMed ID: 34529000
[TBL] [Abstract][Full Text] [Related]
15. Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer.
Haynes BP; Schuster G; Buus R; Alataki A; Ginsburg O; Quang LH; Han PT; Khoa PH; Van Dinh N; Van To T; Clemons M; Holcombe C; Osborne C; Evans A; Skene A; Sibbering M; Rogers C; Laws S; Noor L; Cheang MCU; Cleator SJ; Smith IE; Dowsett M
Breast Cancer Res Treat; 2021 Nov; 190(2):295-305. PubMed ID: 34524591
[TBL] [Abstract][Full Text] [Related]
16. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
[TBL] [Abstract][Full Text] [Related]
17. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
18. Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.
Tombal BF; Freedland SJ; Armstrong AJ; Beer TM; Stenzl A; Sternberg CN; Hussain M; Ganguli A; Ramaswamy K; Bhadauria H; Ivanescu C; Turnbull J; Holmstrom S; Saad F
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):288-295. PubMed ID: 34518652
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
[TBL] [Abstract][Full Text] [Related]
20. Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression.
Augusto TV; Amaral C; Wang Y; Chen S; Almeida CF; Teixeira N; Correia-da-Silva G
Breast Cancer Res Treat; 2021 Nov; 190(2):227-240. PubMed ID: 34498152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
